Plain-English translation of NCT05433935 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying people who have been diagnosed with intraductal papillary mucinous neoplasms (IPMNs)—which are cysts in the pancreas that sometimes turn into cancer. By collecting blood, urine, feces, and saliva samples from thousands of patients over time, the study aims to find biological markers (early warning signs) that can predict whether someone's cyst will become cancerous. This information could help doctors catch cancer earlier and decide who needs surgery.
Right now, doctors struggle to know which pancreatic cysts will become cancer and which ones are safe to watch. By identifying reliable warning signs in body fluids, this research could help doctors make better treatment decisions and potentially save lives by catching cancer at earlier stages.
You likely qualify if…
You likely don't qualify if…
You would be enrolled in a long-term study where you regularly donate biological samples—blood, urine, feces, and saliva—which researchers will analyze to look for early warning signs of cancer. You'll likely have multiple visits over time, and your doctors will track whether your cyst changes, whether you need surgery, and your health outcomes after any procedures. The study plans to follow 5,000 patients to build a comprehensive picture of how pancreatic cysts develop.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China
Sponsor
Zhejiang University
Collaborators
The Second Hospital of Hebei Medical University, Second Affiliated Hospital of Nanchang University
Enrollment target
~5,000 participants
Started
July 2022
Primary completion
June 2032
Age range
0 Years – 90 Years
Last updated on clinicaltrials.gov in January 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Tingbo Liang, PhD
Zhejiang University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.